TheraRadar
Data updated: May 26, 2026

DESVENLAFAXINE SUCCINATE

CNS Approved 2015-06-29

DESVENLAFAXINE SUCCINATE is indicated for the treatment of Major Depressive Disorder.

Source: FDA Label • Lupin
8
Indications
--
Phase 3 Trials
10
Years on Market

Details

Status
Prescription
First Approved
2015-06-29
Routes
ORAL
Dosage Forms
TABLET, EXTENDED RELEASE

DESVENLAFAXINE SUCCINATE Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
121 FDA actions from 2015 to 2026
Mar 2026 ORIGINAL
Update
Apr 2025 SUPPL
Label · Labeling
Jan 2025 ORIGINAL
Update

What DESVENLAFAXINE SUCCINATE Treats

1 indications

DESVENLAFAXINE SUCCINATE is approved for 1 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Major Depressive Disorder
Source: FDA Label

DESVENLAFAXINE SUCCINATE Boxed Warning

BOXED WARNING WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see WARNINGS AND PRECAUTIONS ( 5.1 )]. In patients of all ages who are started on antidepre...

DESVENLAFAXINE SUCCINATE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to DESVENLAFAXINE SUCCINATE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

APLENZIN
BUPROPION HYDROBROMIDE
1 shared
BAUSCH
Shared indications:
AUVELITY
BUPROPION HYDROCHLORIDE
1 shared
AXSOME
Shared indications:
CAPLYTA
LUMATEPERONE TOSYLATE
1 shared
INTRA-CELLULAR
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DESVENLAFAXINE SUCCINATE FDA Label Details

Indications & Usage

DESVENLAFAXINE SUCCINATE is indicated for the treatment of Major Depressive Disorder.

⚠️ BOXED WARNING

BOXED WARNING WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use i...

Looking for the branded version?

PRISTIQ

Full clinical data, patents, trials, and competitive landscape for desvenlafaxine succinate.

See PRISTIQ

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.